A clinical trial found that nanopharmaceutical drug CRLX101 is showing promise as a potential new treatment for cancers that develop resistance to antiangiogenic drugs and radiation therapy. The results of the trials were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19 - 23.
Antiangiogenic drugs are anticancer drugs designed to cut off the blood supply that brings tumors the nutrients they need to grow and survive, thereby starving and killing the tumor cells. Over time, however, tumors usually develop resistance to these drugs, often because of the upregulation of a protein called HIF-1 alpha. This protein promotes tumor invasion, metastasis, and cancer stem cell formation, all of which make tumors more aggressive and unmanageable. Antiangiogenesis drugs, as a result, have achieved limited success in the treatment of cancers.
"Reducing or eliminating resistance to antiangiogenic drugs could have meaningful implications for cancer patients. Up until now, HIF-1alpha has been considered impossible to target safely, but CRLX101 may change that," said Scott Eliasof, Ph.D., vice president of Cerulean Pharma Inc., in Cambridge, Mass. "CRLX101 has been shown to inhibit HIF-1alpha, and the clinical data we have obtained to date suggest that it has limited side effects, which may permit it to be effectively combined with other drugs." We believe that CRLX101 may have the potential to manage resistance to antiangiogenic and radiation therapies.
"Based on our preclinical data, we believe CRLX101 may have the potential to have a significant effect on pathological complete response in rectal cancer patients and on overall survival duration in patients with ovarian and kidney cancers," he added. CRLX101's payload is the toxic anticancer drug, camptothecin, chemically conjugated into nanoparticles of 20-30 nanometers in diameter, using polymeric materials. When CRLX101 is taken up by the tumor cells, preclinical data suggest that the chemical linkers release the payload slowly, ensuring a steady and sustained release of camptothecin over time. This sustained drug release enables durable inhibition of an enzyme called topoisomerase-1, which leads to the inhibition of HIF-1 alpha. Eliasof and colleagues have initiated four phase II investigator-sponsored clinical trials to test CRLX101 either as a single agent or in combination with an antiangiogenic drug.
In one phase Ib/IIa trial, they have recruited nine patients to date with kidney cancer, a cancer that is known to have high levels of HIF-1alpha. All patients had received prior antiangiogenesis therapy with limited success. When treated in this trial with CRLX101 in combination with the antiangiogenic drug bevacizumab, the researchers observed a 33 percent partial response rate in these patients, which is unprecedented according to Eliasof, because the overall response rate is typically 4 percent with bevacizumab alone and 2% with everolimus, the standard of care in this setting. Of note, the maximum tolerated dose of CRLX101 in combination with bevacizumab is the same as the monotherapy dose, suggesting it has low toxicity and higher tolerability.
"Nine patients is a small sample size, but we are cautiously optimistic," he said. An imaging clinical trial in patients with gastric cancers testing CRLX101 revealed more accumulation of the drug in tumors than in the neighboring healthy tissue, suggesting the compound has the potential to be target specific. Two clinical trials to test CRLX101 as monotherapy in small-cell lung cancer and ovarian cancer are underway. Before year-end, Cerulean plans to launch two additional combination trials, according to Eliasof. The first clinical trial will combine CRLX101 with bevacizumab in ovarian cancer. The second clinical trial will combine CRLX101 with capecitabine and radiation in neoadjuvant rectal cancer.
"We have generated compelling preclinical data showing synergy when CRLX101 is combined with every antiangiogenic agent we have tested to date. Our focus now is on making a difference in the lives of patients in our various clinical trials."